This CC was a little premature, however I will always welcome hearing updates on all fronts. I will take way from this call that we will be up-listed to a major stock exchange in June 2020 if all goes as planned. Also, this will coincide with the possibility of submitting interim trial data to the FDA for 50 patients in mild to moderate Covid-19 study. This positions the company nicely for opening 10 phase 2 trials and a Monotherapy phase 3 trial. Good stuff …..Let's keep it positive. We have quite a bit to be thankful for right now.